We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Capricor Therapeutics Inc (CAPR) USD0.001

Sell:$3.70 Buy:$3.95 Change: $0.02 (0.52%)
Market closed |  Prices as at close on 21 February 2024 | Switch to live prices |
Change: $0.02 (0.52%)
Market closed |  Prices as at close on 21 February 2024 | Switch to live prices |
Change: $0.02 (0.52%)
Market closed |  Prices as at close on 21 February 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Capricor Therapeutics, Inc. is a biotechnology company. The Company is focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases. The Company’s lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy that is in late-stage clinical development for treating Duchenne muscular dystrophy (DMD). CAP-1002 is designed to slow disease progression in DMD through the immunomodulatory, anti-inflammatory, and anti-fibrotic actions of cardiosphere-derived cells (CDCs), which are mediated by secreted exosomes laden with bioactive cargo. CAP-2003 is the name of its exosomes product candidate, which is derived from its CDCs. It is also developing its exosome technology as a therapeutic platform. The Company’s focus is on developing exosomes capable of delivering nucleic acids, including messenger RNA (mRNA), as well as proteins to treat or prevent a variety of diseases.

Contact details

8840 Wilshire Blvd, 2nd Floor
United States
+1 (310) 3583200

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$111.16 million
Shares in issue:
30.79 million
United States
US dollar

Key personnel

  • Frank Litvack
    Executive Chairman of the Board
  • Linda Marban
    President, Chief Executive Officer, Director
  • Anthony Bergmann
    Chief Financial Officer
  • Karen Krasney
    Executive Vice President, General Counsel

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.